AM-Pharma B.V.
|
AM-Pharma B.V. Employees in Amsterdam: 17 |
Company Profile
AM-Pharma is a biopharmaceutical company, based in Bunnik, The Netherlands. The company is focused on the pre-clinical and clinical development of novel therapeutics to treat inflammatory diseases and infectious diseases. All our products address high medical needs and commercially attractive markets.
Our products are based on endogenous proteins and (protein derived) peptides, optimised to fight inflammatory diseases and infections. AM-Pharma has intellectual property around two scientific platforms:
- Enhancing Toll Like Receptor mediated activation of innate immune cells
- Dephosphorylation of extracellular substrates to influence disease processes
So far, AM-Pharma has developed two products originating from its intellectual property franchise, Alkaline Phosphatase and hLF1-11 up to the point of initial proof of clinical efficacy and safety.
AM-Pharma currently employs 17 people. We out-source all non-core know how dependent development work to specialist third party organisations.
Once our products have shown to be safe and effective in patients we out-license our products to collaboration partners who become responsible for further development and worldwide marketing.
Science and Technologies or Services
Alkaline Phosphatase (AP) (acute renal failure and ulcerative colitis)
The endogenous enzyme alkaline phosphatase is expressed in various tissues throughout the human body including kidney and GI tract. AP has been shown to dephosphorylate LPS to a non-toxic form that acts as a partial antagonist on the LPS receptor complex. In addition to LPS, AP can dephosphorylate different other substrates e.g. ATP and through this dephosphorylation interfere with inflammatory response and associated tissue damage. Proof of concept has been shown in Phase IIa Proof Of Concept trials in Acute Renal Failure and Ulcerative Colitis.
HLF 1-11 Anti microbial peptide
The antimicrobial peptide hLF1-11 comprises the first 11 N-terminal amino acids of the endogenous protein; human lactoferrin. The compound exerts both antibacterial and antifungal activity against a broad range of microorganisms. Moreover, it appears that hLF1-11 has a low propensity to generate resistance in microorganisms, because it acts by stimulating the innate immune system. Phase IIa Proof Of Concept trials have are in preparation in MRSA infections and systemic Candida infections.
Keywords
- Acute Renal Failure
- Ulcerative Colitis
- MRSA
- Systemic candida infection
- Phase II clinical development
- Anti-infective
- Anti-inflammatory
